ScreenerHero

VANIVivani Medical Inc. Common Stock

NAS · US · Healthcare · Biotechnology · vivani.com
1.380USD-0.72%Mkt Cap: 124.48M $P/E: —

Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap124.48M $
Enterprise Value125.15M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.61M $
Revenue/Share—
Last Price1.380 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees42
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.03
PEG—
EV/EBITDA-4.66
EV/Revenue—
P/S—
P/B6.65
EPS (TTM)-0.36
EPS (Forward)-0.35
52W Range
0.923046% of range1.920
52W High1.920 USD
52W Low0.9230 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-169.16%
ROA-67.55%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.32M $
CapEx (TTM)1.17M $
FCF Margin—
FCF Yield-13.43%
Net Debt-2.04M $
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity1.20
Current Ratio3.25
Quick Ratio3.09
Book Value/Sh0.2120 USD
Cash/Share0.2210 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 6, 2020
Splits
Last Split1:3
Split DateAug 19, 2022
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.833 USD
Upside (mean)+177.8%
Target Range3.500 USD – 4.000 USD
$3.500+177.8% to mean$4.000
# Analysts3
Ownership
Shares Out.90.20M
Float36.50M
Insiders55.39%
Institutions5.89%
Short Interest
Short Ratio0.5d
Short % Float1.15%
Short % Out.0.58%
Shares Short498.17K
Short (prev mo.)432.66K
Technical
SMA 501.311 (+5.3%)
SMA 2001.288 (+7.1%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)282.70K
Avg Vol (10d)228.33K
Technical Indicators
RSI (14)53.1
MACD0.0191
MACD Signal0.0210
MACD Hist.-0.0019
BB Upper1.448 USD
BB Middle1.351 USD
BB Lower1.255 USD
BB Width14.28%
ATR (14)0.0879 USD
Vol Ratio (20d)0.60x